Senior Manager, Marketing

Canada

Auto‑apply with AI Apply

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

BiopharmaceuticalsIndustries

Requirements

Candidates should possess a Bachelor’s degree in a relevant discipline and a minimum of 5 years of progressively responsible commercial experience in a pharmaceutical, biotechnology, or related environment, with at least 4 years in marketing roles, and preference given to experience in rare disease. Demonstrated success in supporting the execution of key marketing tactics, including promotional material development and digital strategy implementation is required. Experience working across business models of Patient Support Programs is also desired.

Responsibilities

The Senior Manager, Marketing will be responsible for the development and execution of marketing strategies and tactics for the assigned product(s) in Canada, collaborating closely with cross-functional teams and US/Global Marketing teams. They will contribute to tactic development, congress/virtual event activities, and digital programs, analyze commercial data, work with internal and external partners to manage contracts and budgets, maintain relationships with agency partners, ensure compliance with regulations, and perform other tasks as needed.

Skills

Marketing Strategy

Cross-functional Collaboration

Brand Management

Regulatory Compliance

Project Leadership

Strategic Planning

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters

2012Year Founded

$430.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Performance Bonus

Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.

Potential delays in AXS-07 launch amid growing market anticipation.

Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.

AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.

Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.

Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.

Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI

Try Jobo Free